Novel Mad2-targeting miR-493-3p controls mitotic fidelity and cancer cells' sensitivity to paclitaxel.
Tambe M, Pruikkonen S, Mäki-Jouppila J, Chen P, Elgaaen BV, Straume AH, Huhtinen K, Cárpen O, Lønning PE, Davidson B, Hautaniemi S, Kallio MJ.
Tambe M, et al. Among authors: straume ah.
Oncotarget. 2016 Mar 15;7(11):12267-85. doi: 10.18632/oncotarget.7860.
Oncotarget. 2016.
PMID: 26943585
Free PMC article.